The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Subscribe To Our Newsletter & Stay Updated
